SCHEMBL18572275

SCHEMBL18572275

Cc1ccc(S(=O)(=O)N/N=C/[C@H]2O[C@@H](n3ccc4c(Cl)ncnc43)[C@@H]3OC(C)(C)O[C@@H]32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ PRMT5 O14744 10/20 0.36
▸ WDR77 Q9BQA1 10/20 0.36
▸ ALDH1A1 P00352 6/20 0.33
▸ RECQL P46063 2/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25951483 1.00 KMT2A (0.38) KMT2ATDP1MEN1MAPTNPC1
SCHEMBL18571963 0.87 RXFP1 (0.37) KMT2ATDP1MEN1MAPTNPC1
SCHEMBL22002061 0.83 KMT2A (0.36) KMT2ATDP1MEN1MAPTNPC1
SCHEMBL18571954 0.83 KMT2A (0.36) KMT2ATDP1MEN1MAPTNPC1
SCHEMBL18572278 0.80 ALDH1A1 (0.33) KMT2ATDP1MEN1MAPTNPC1
SCHEMBL18571918 0.79 PRMT5 (0.42) PRMT5WDR77RAPGEF3
SCHEMBL25951474 0.77 KMT2A (0.37) KMT2ATDP1MEN1MAPTNPC1
SCHEMBL21089769 0.77 PRMT5 (0.40) PRMT5WDR77
SCHEMBL22683096 0.76 RXFP1 (0.49) PRMT5WDR77RXFP1RAPGEF3
SCHEMBL18572012 0.76 RXFP1 (0.49) PRMT5WDR77RXFP1RAPGEF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 — — US disclosed
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 — — US disclosed
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-11-19 — — US disclosed
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 — — US disclosed
WO-2017032840-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 KMT2A 153/4885TDP1 384/4885MEN1 2728/4885
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 KMT2A 151/4885TDP1 362/4885MEN1 3275/4885
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 KMT2A 193/4885TDP1 433/4885MEN1 2634/4885
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 KMT2A 153/4885TDP1 384/4885MEN1 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback